Samuel R Pearlman

Title: Samuel R. Pearlman: Innovator in Monoclonal Antibody Development

Introduction

Samuel R. Pearlman is a notable inventor based in Davie, FL (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for the detection of various viruses, showcasing his expertise and innovation in this critical area of research.

Latest Patents

Samuel R. Pearlman holds a patent for a monoclonal antibody designed for detecting HTLV-I, HTLV-II, and STLV-I viruses. This patent describes a hybrid cell line capable of producing monoclonal antibodies that bind to the core antigens p24 and p53 of HTLV-I and HTLV-II, while not binding to the p19 core antigen. Additionally, the antibody is effective against core antigens of simian T-cell leukemia virus Type I (STLV-I). The monoclonal antibody is identified as the KC-88 monoclonal antibody, and the cell line producing it has been deposited in the American Type Culture Collection, Rockville, MD, with the assigned A.T.C.C. Deposit No. HB 10562.

Career Highlights

Samuel R. Pearlman is associated with Coulter Corporation, where he has contributed to advancements in medical technology and diagnostics. His work has been instrumental in enhancing the understanding and detection of viral infections, which is crucial for public health.

Collaborations

Throughout his career, Samuel has collaborated with notable colleagues, including David E. Hofheinz and Gary P. Toedter. These collaborations have fostered innovation and have led to significant advancements in their respective fields.

Conclusion

Samuel R. Pearlman's contributions to the field of monoclonal antibodies exemplify his dedication to scientific innovation. His work continues to impact the detection of important viruses, highlighting the importance of research and development in biotechnology.